<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00168064</url>
  </required_header>
  <id_info>
    <org_study_id>2005NMMF-201-US</org_study_id>
    <nct_id>NCT00168064</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides</brief_title>
  <official_title>A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.02% Ointment Formulations in Patients With Stage I or IIA Mycosis Fungoides (MF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yaupon Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yaupon Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, tolerability and safety of the topical application of
      mechlorethamine (MCH) formulations in patients with stage I or IIA mycosis fungoides (MF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The successful use of mechlorethamine (MCH) as a topical agent in the treatment of mycosis
      fungoides, a form of cutaneous T-cell lymphoma, was first reported in the late 1950s, and
      provided a rationale for skin-directed chemotherapy that minimized systemic toxicity. Since
      then, multiple investigators have demonstrated the safety and efficacy of topically applied
      MCH in the treatment of mycosis fungoides. This study will evaluate the efficacy
      (non-inferiority), tolerability and safety of topical application of MCH proprietary gel
      versus a compounded ointment formulation in Aquaphor in patients with stage I or IIA MF.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of Response Rates Based on CAILS</measure>
    <time_frame>Assessment made at Day 1 and every subsequent visit during treatment</time_frame>
    <description>The ratio of the response rate of the patients treated with the PG formulation to the response rate of the patients treated with the AP formulation. Skin response determined by at least a 50% reduction from baseline in the Composite Assessment of Index Lesion Severity (CAILS) following up to 12 months of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity-weighted Assessment Tool (SWAT) Within up to 12 Months by 2 or More Consecutive Observations Over at Least 4 Weeks</measure>
    <time_frame>Assessment made at Day 1 and every subsequent visit during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Achieving at Least 50% Improvement of Severity Weighted Assessment Tool (SWAT)</measure>
    <time_frame>Baseline to end of therapy</time_frame>
    <description>Assessment of lesion distribution and severity. A responder analysis was performed on whether subject achieved at least 50% improvement on scale. This had to be confirmed on at least one visit at least 4 weeks apart.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Mycosis Fungoides</condition>
  <arm_group>
    <arm_group_label>1 (PG - NM (MCH) 0.02%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PG - mechlorethamine-MCH (nitrogen mustard) 0.02% gel To evaluate the tolerability and safety of topical mechlorethamine-MCH (nitrogen mustard) 0.02% ointment formulations in patients with stage I or IIA MF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 (AP - MCH(NM) 0.02%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AP - mechlorethamine-MCH (nitrogen mustard) 0.02% compounded in Aquaphor To evaluate the tolerability and safety of mechlorethamine-MCH (nitrogen mustard)0.02% ointment formulations in patients with stage I or IIA MF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mechlorethamine-MCH (nitrogen mustard)</intervention_name>
    <description>All affected areas (lesions) are to be treated once daily for twelve months with mechlorethamine-MCH (nitrogen mustard) 0.02% PG or NM 0.02% AP ointment</description>
    <arm_group_label>1 (PG - NM (MCH) 0.02%)</arm_group_label>
    <arm_group_label>2 (AP - MCH(NM) 0.02%)</arm_group_label>
    <other_name>mechlorethamine</other_name>
    <other_name>nitrogen mustard</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with mycosis fungoides confirmed by a skin biopsy

          -  Stage I or IIA patients must have been treated previously with prior topical therapies
             including PUVA, UVB, topical steroids, but not NM within the past 2 years, or topical
             carmustine (BCNU)

          -  Patients must be otherwise healthy with acceptable organ function.

          -  Prior to initiating study therapy, patients must not have had topical therapy within
             four weeks

          -  Lab values within normal range

          -  Willing/able to give consent

          -  Must use effective means of contraception if of childbearing potential

        Exclusion Criteria:

          -  Newly diagnosed mycosis fungoides with no prior therapy

          -  A prior history of treatment with topical NM within the past 2 years or topical
             carmustine (BCNU)

          -  Use of topical or systemic therapies for MF within four (4) weeks of entry in the
             study

          -  Patients with a diagnosis of stage IIB-IV MF

          -  Serious known concurrent medical illness or infection, which could potentially present
             a safety risk and/or prevent compliance with the requirements of the treatment program

          -  Pregnant or nursing females, or males and females of childbearing potential, not using
             an effective means of contraception

          -  Patients who have had radiation therapy within one year of study start

          -  Patients who have a history of a higher T score than T2 or a higher N score than N1

          -  Patients who do not agree to do all labs at one site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Lessin, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University - Dept. of Dermatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>61611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Medical Center Dept. of Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University, Dept. of Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas, M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Clinical Trials, LLC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53791</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003 Feb;139(2):165-73.</citation>
    <PMID>12588222</PMID>
  </reference>
  <reference>
    <citation>Kim YH. Management with topical nitrogen mustard in mycosis fungoides. Dermatol Ther. 2003;16(4):288-98. Review.</citation>
    <PMID>14686971</PMID>
  </reference>
  <reference>
    <citation>Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol. 1996 Nov;132(11):1309-13.</citation>
    <PMID>8915308</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <results_first_submitted>July 12, 2011</results_first_submitted>
  <results_first_submitted_qc>October 2, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 31, 2012</results_first_posted>
  <last_update_submitted>October 2, 2012</last_update_submitted>
  <last_update_submitted_qc>October 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mycosis Fungoides</keyword>
  <keyword>Nitrogen Mustard</keyword>
  <keyword>Cutaneous T-Cell Lymphoma</keyword>
  <keyword>CTCL - Mycosis Fungoides</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PG -Mechlorethamine (Nitrogen Mustard) 0.02% PG Gel</title>
          <description>Study formulation of Mechlorethamine-MCH (Nitrogen Mustard) 0.02% Gel</description>
        </group>
        <group group_id="P2">
          <title>AP- Mechlorethamine 0.02% Compounded in Aquaphor</title>
          <description>Compounded Mechlorethamine-MCH (Nitrogen Mustard) in Aquaphor 0.02%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="130">128 participants received PG formulation</participants>
                <participants group_id="P2" count="130">127 participants received AP formulation</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Concurrent Illness</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject's Best interest</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Various</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PG -Mechlorethamine-MCH (Nitrogen Mustard) 0.02% PG Gel</title>
          <description>Study formulation of mechlorethamine-MCH (Nitrogen Mustard) 0.02% Gel</description>
        </group>
        <group group_id="B2">
          <title>AP- Mechlorethamine-MCH (NM) 0.02% Compounded in Aquaphor</title>
          <description>Compounded mechlorethamine-MCH (Nitrogen Mustard)in Aquaphor 0.02%</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="130"/>
            <count group_id="B2" value="130"/>
            <count group_id="B3" value="260"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.7" spread="14.20"/>
                    <measurement group_id="B2" value="56.7" spread="14.34"/>
                    <measurement group_id="B3" value="55.7" spread="14.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ratio of Response Rates Based on CAILS</title>
        <description>The ratio of the response rate of the patients treated with the PG formulation to the response rate of the patients treated with the AP formulation. Skin response determined by at least a 50% reduction from baseline in the Composite Assessment of Index Lesion Severity (CAILS) following up to 12 months of treatment</description>
        <time_frame>Assessment made at Day 1 and every subsequent visit during treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>PG- Mechlorethamine-MCH (Nitrogen Mustard) 0.02% Gel</title>
            <description>Study formulation of mechlorethamine-MCH (Nitrogen Mustard) 0.02% Gel</description>
          </group>
          <group group_id="O2">
            <title>AP- Aquaphor Formulation Mechlorethamine-MCH (NM) 0.02%</title>
            <description>Mechlorethamine-MCH (Nitrogen Mustard) compounded in Aquaphor 0.02%</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Response Rates Based on CAILS</title>
          <description>The ratio of the response rate of the patients treated with the PG formulation to the response rate of the patients treated with the AP formulation. Skin response determined by at least a 50% reduction from baseline in the Composite Assessment of Index Lesion Severity (CAILS) following up to 12 months of treatment</description>
          <population>ITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The PG formulation was determined to be non-inferior to the AP formulation if the lower limit of the 95% confidence interval around the ratio of the response rates (PG/AP) was &gt; = 0.75.</non_inferiority_desc>
            <param_type>ratio of proportions</param_type>
            <param_value>1.226</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.974</ci_lower_limit>
            <ci_upper_limit>1.552</ci_upper_limit>
            <estimate_desc>ratio is response rate of PG formulation divided by response rate of AP formulation</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity-weighted Assessment Tool (SWAT) Within up to 12 Months by 2 or More Consecutive Observations Over at Least 4 Weeks</title>
        <time_frame>Assessment made at Day 1 and every subsequent visit during treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Achieving at Least 50% Improvement of Severity Weighted Assessment Tool (SWAT)</title>
        <description>Assessment of lesion distribution and severity. A responder analysis was performed on whether subject achieved at least 50% improvement on scale. This had to be confirmed on at least one visit at least 4 weeks apart.</description>
        <time_frame>Baseline to end of therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PG -Mechlorethamine-MCH (Nitrogen Mustard) 0.02% PG Gel</title>
            <description>Study formulation of mechlorethamine-MCH (Nitrogen Mustard) 0.02% Gel</description>
          </group>
          <group group_id="O2">
            <title>AP- Mechlorethamine-MCH (NM) 0.02% Compounded in Aquaphor</title>
            <description>Compounded mechlorethamine-MCH (Nitrogen Mustard) in Aquaphor 0.02%</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Achieving at Least 50% Improvement of Severity Weighted Assessment Tool (SWAT)</title>
          <description>Assessment of lesion distribution and severity. A responder analysis was performed on whether subject achieved at least 50% improvement on scale. This had to be confirmed on at least one visit at least 4 weeks apart.</description>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>adverse event data were collected over 12 months of the patient's participation</time_frame>
      <desc>There were a total of 130 participants randomized to each treatment arm. However, 2 from the PG group and 3 from the AP group did not receive drug and are not included in the safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>PG -Mechlorethamine-MCH (Nitrogen Mustard) 0.02% PG Gel</title>
          <description>Study formulation of mechlorethamine-MCH (Nitrogen Mustard) 0.02% Gel</description>
        </group>
        <group group_id="E2">
          <title>AP- Mechlorethamine-MCH (NM) 0.02% Compounded in Aquaphor</title>
          <description>Compounded mechlorethamine-MCH (Nitrogen Mustard)in Aquaphor 0.02%</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>folliculitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="128"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="128"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin irritation</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="128"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="128"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>erythema</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="128"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>dermatitis contact</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="128"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="128"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>H. Jeffrey Wilkins, MD</name_or_title>
      <organization>Yaupon Therapeutics</organization>
      <phone>4843247935 ext 935</phone>
      <email>hjwilkins@yaupontherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

